The utility of a model-based cost-effectiveness analysis of degarelix versus leuprolide in the therapy of hormone-dependent advanced prostate cancer. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 14, n. 3, p. 131–146, 2013. DOI: 10.7175/fe.v14i3.700. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/700. Acesso em: 15 feb. 2026.